CCUL ETF: what CCUL.TO is, what it holds, and how it works

Short answer: CCUL.TO is the Counterpoint Global CIBC U.S. Large Cap Growth ETF, listed on the TSX on May 28, 2026, at a 0.50% management fee. CIBC manages the Canadian wrapper; Counterpoint Global, a team at Morgan Stanley Investment Management, runs the strategy: concentrated, high-conviction investing in U.S. large-cap growth companies. It’s genuinely active stock-picking, not an index fund, and the full MER isn’t published yet because it’s in its first year.

CCUL is one of four ETFs CIBC launched in May 2026 with Counterpoint Global. It’s worth understanding because it’s a different animal from the Avantis CIBC funds people have been talking about: where Avantis tilts broadly toward value across hundreds of names, Counterpoint runs a concentrated, conviction-led growth portfolio. This walks through what CCUL is, who Counterpoint is, and how to think about it.

This is not financial advice. I’m sharing what I’ve learned from my own research, and your situation might differ. Fund details change, so always check the current disclosures before deciding.

What CCUL actually is

CCUL.TO is an ETF listed on the TSX in Canadian dollars. CIBC Asset Management handles the wrapper, listing, and disclosure. The portfolio is run by Counterpoint Global, an investment team within Morgan Stanley Investment Management.

It invests primarily in large-capitalization U.S. companies that the team believes can grow their value significantly over the long term. This is active management in the truest sense: a research team picking a relatively small number of companies it has conviction in, not a fund mechanically tracking an index.

CCUL fund facts

Attribute	Value
Ticker	CCUL (TSX)
Full name	Counterpoint Global CIBC U.S. Large Cap Growth ETF
Listed	May 28, 2026
Strategy	Active, concentrated U.S. large-cap growth
Management fee	0.50%
MER	Not yet published (first-year rule)
Manager	CIBC, sub-advised by Counterpoint Global (Morgan Stanley)
Role in a portfolio	Active growth sleeve, not a core index holding

Who is Counterpoint Global

This is the part that defines the fund. Counterpoint Global is a team at Morgan Stanley Investment Management led by Dennis Lynch, with Michael Mauboussin as head of consilient research. They’ve built a reputation in the U.S. for concentrated, high-conviction, long-horizon growth investing: holding a relatively small number of companies they believe have durable, underappreciated growth, and being willing to look very different from the index.

That last point matters. A Counterpoint portfolio is “highly differentiated from its benchmark,” which is the polite way of saying it will behave very differently from the S&P 500, sometimes much better, sometimes much worse. It’s the opposite of a closet index fund.

How this differs from the Avantis CIBC funds

If you’ve read about the Avantis CIBC lineup, it’s worth being clear that Counterpoint is a different philosophy entirely, even though both sit under the CIBC ETF roof.

• Avantis is rules-based and broadly diversified. It tilts toward value, smaller, and profitable companies across hundreds of names. Cheap, systematic, factor-driven.
• Counterpoint is discretionary and concentrated. It picks a smaller number of growth companies based on fundamental research and conviction. More expensive, more active, more benchmark-divergent.

They’re close to opposites: value tilt versus growth conviction, systematic versus discretionary, diversified versus concentrated. Neither is “better.” They’re different bets, and CCUL is firmly on the active-growth side.

Where CCUL fits

CCUL is an active growth sleeve, not a core holding. It makes sense for an investor who knows Counterpoint’s track record, wants concentrated U.S. growth exposure, and accepts both the higher fee and the real chance of trailing the index for long stretches. It’s a satellite position for most people who use it at all, not the foundation of a portfolio.

For broad, cheap U.S. large-cap exposure, a plain S&P 500 or total-market index fund does that job at a fraction of the cost. CCUL only earns its fee if you specifically believe in the active approach.

Frequently asked questions

What is CCUL.TO?

CCUL.TO is the Counterpoint Global CIBC U.S. Large Cap Growth ETF, listed on the TSX on May 28, 2026. CIBC manages the wrapper and Counterpoint Global, a team at Morgan Stanley Investment Management, runs the strategy: concentrated, active investing in U.S. large-cap growth companies. It trades in Canadian dollars.

What is CCUL’s MER?

The management fee is 0.50%. The full MER hasn’t been published yet because Canadian regulators don’t require it in a fund’s first year. Expect it a few basis points above 0.50% once disclosed. That’s well above a plain index fund, reflecting the active management.

Is CCUL actively managed?

Yes, fully. Unlike the rules-based Avantis CIBC funds, CCUL is discretionary active management: a research team selecting a concentrated set of companies based on conviction, not tracking an index. It’s designed to look different from its benchmark, which means it can outperform or underperform meaningfully.

How is CCUL different from the Avantis CIBC funds?

Both sit under CIBC, but the philosophies are opposite. Avantis is systematic, low-cost, broadly diversified, and tilts toward value. Counterpoint is discretionary, more expensive, concentrated, and growth-focused. CCUL is an active-growth bet; the Avantis funds are systematic factor funds.

Can I hold CCUL in a TFSA or RRSP?

Yes. CCUL trades on the TSX in Canadian dollars and is eligible in any standard Canadian registered account (TFSA, RRSP, FHSA, RESP, RDSP, RRIF, LIRA) as well as non-registered accounts.

Bottom line

CCUL brings a well-regarded U.S. growth team, Counterpoint Global, to Canadian investors in a single ticker. It’s concentrated, active, and priced like it at 0.50%. That’s the right tool for someone who specifically wants this kind of high-conviction growth exposure and accepts the manager risk and benchmark divergence that come with it. For plain U.S. large-cap exposure, a low-cost index fund remains the simpler, cheaper choice.